In this CME-certified video for primary care, experts discuss how to best communicate with patients to ensure proper diagnosis and optimal treatment strategies for IBS.
Professor of Medicine
Vatche and Tamar Manoukian Division of Digestive Diseases
David Geffen School of Medicine at UCLA
Los Angeles, California
University of Michigan Health System
Nostrant Collegiate Professor of Gastroenterology & Nutrition Sciences
Division of Gastroenterology
Ann Arbor, Michigan
Associate Director, Scientific Services
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Gastroenterological Association, Clinical Care Options, and the activity supporter do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the American Gastroenterological Association, Clinical Care Options, and the activity supporter. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for physicians, physician assistants, nurse practitioners, nurses, and other healthcare providers who care for patients with IBS or CIC.
American Gastroenterological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
American Gastroenterological Association designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 19, 2019, through December 18, 2020:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Enter asthma patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts
Slide from CCO on the importance of vaccinating older adults against shingles, with examples of how to overcome common clinical challenges.
From EULAR 2020, new data from RABBIT trial assessing risk of herpes zoster infection among RA patients by class of DMARD, as reported by CCO
New from EULAR 2020: risk of JAKi, IL-6i, abatacept vs TNFi discontinuation among patients with rheumatoid arthritis, as reported by Clinical Care Options (CCO)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.